Neoadjuvant Immune Checkpoint Inhibition in MSI-H/dMMR Colorectal Cancer: A Systematic Review of Prospective Trials Evaluating Efficacy, Pathologic Response, and Surgical Outcomes [0.03%]
错配修复缺陷型结直肠癌新辅助免疫治疗：一项关于疗效、病理反应和手术结果的前瞻性研究系统评价
Wajahat Mirza,Mehak Ejaz Khan,Hania Iqbal et al.
Wajahat Mirza et al.
Background: Mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI-H) colorectal cancers demonstrate exceptional responsiveness to immune checkpoint inhibitors; however, evidence for the efficacy of neo...
Sociodemographic Determinants Associated with the Receipt of Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Population-Based Study from the SEER Registry [0.03%]
基于SEER登记处III期结直肠癌辅助化疗影响因素的流行病学研究
Sameh Hany Emile,Nir Horesh,Zoe Garoufalia et al.
Sameh Hany Emile et al.
Background: Approximately 35% of patients do not receive adjuvant chemotherapy (AC) after surgery for stage III colorectal cancer (CRC). We aimed to investigate the association between receipt of AC and sociodemographic a...
Correction: Diagnostic Utility of Serum CEA and Ca 19.9 as Triage Tools for Predicting Metastatic Disease in Gallbladder Cancer: A Sub-analysis from a Prospective Observational Study [0.03%]
纠正：针对前瞻性观察性研究中胆囊癌远处转移预测的血清CEA和CA19.9诊断价值的亚组分析
Kumar Vineet,Mayank Tripathi,Chandan Kumar et al.
Kumar Vineet et al.
Published Erratum
Journal of gastrointestinal cancer. 2025 Dec 3;56(1):235. DOI:10.1007/s12029-025-01360-3 2025
Bioinformatics Analysis Reveals the Role of DLGAP4 in the Development and Progression of Hepatocellular Carcinoma [0.03%]
生物信息学分析揭示DLGAP4在肝细胞癌发生发展中的作用
Feng Yang,Shoufeng Chang,Ruxia Li et al.
Feng Yang et al.
Purpose: Although the DLGAP4 gene is well-established in neurological disorders, its function in hepatocellular carcinoma (HCC) remains unclear. This study aims to characterize DLGAP4 expression patterns, prognostic signi...
Clinical Efficacy and Safety of Gemcitabine-Cisplatin Combination in Metastatic Gallbladder Cancer: A Prospective Study from North India [0.03%]
吉西他滨-顺铂新组合方案治疗胆囊癌转移的临床疗效和安全性：一项来自印度北部的研究
Abhinav Dewan,Vineet Talwar,Varun Goel et al.
Abhinav Dewan et al.
Background: Gemcitabine-cisplatin doublet is a standard first-line regimen for metastatic gallbladder cancer (GBC), though prospective real-world data remains scarce. We evaluated the efficacy, safety, and prognostic fact...
Re-evaluating Gastric Ulcer Re-evaluation: Low Malignancy Yield and High Cost in a 19-Year Retrospective Cohort Study [0.03%]
胃溃疡复查的再评价：19年回顾性队列研究中的低癌变率和高成本
Thomas Matthews,Mark Vesey,Aditya Billur et al.
Thomas Matthews et al.
Background: Routine endoscopic re-evaluation of gastric ulcers (GUs) is widely recommended to exclude malignancy. However, in modern practice, particularly in low-to-intermediate gastric cancer prevalence settings, the di...
Role of 18FDG PET-CT & MRI for Predicting Response to Neo-Adjuvant Therapy in Rectal Cancer [0.03%]
18FDG PET-CT及MRI在预测直肠癌新辅助治疗疗效中的作用
Kaushik Jaganathan,Shaifali Goel,Abhishek Aggarwal et al.
Kaushik Jaganathan et al.
Purpose: Neoadjuvant chemoradiotherapy (NACRT) is standard for locally advanced rectal cancer. Accurate response assessment is essential, particularly to identify complete responders eligible for organ-preserving strategi...
Radioembolization in Hepatocellular Carcinoma: Indications and Outcomes [0.03%]
放射性微球栓塞治疗肝细胞癌的指征和疗效研究进展
Bahareh Gholami,Ali Afrasiabi,Paolo Varela et al.
Bahareh Gholami et al.
Hepatocellular carcinoma (HCC) continues to rank among the most common causes of cancer-associated deaths, especially since a large number of patients cannot undergo curative resection or transplantation. For HCC patients, transarterial rad...
Local Recurrence Rates in Locally Advanced Rectal Cancer Are Higher with KRAS Codon 13 Mutations [0.03%]
KRAS第13密码子突变的局部进展期直肠癌局部复发率更高
Richard Sassun,Annaclara Sileo,Jyi Cheng Ng et al.
Richard Sassun et al.
Purpose: Despite advances in oncology regimens and standardization of technical approaches such as total mesorectal excision (TME), local recurrences (LR) remain a significant concern in rectal cancer. This may be due to ...